| Jul 3 |
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
|
| Jul 3 |
Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
|
| Jun 21 |
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
|
| Jun 17 |
Atara Biotherapeutics announces reverse split to regain Nasdaq compliance
|
| Jun 17 |
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
|
| Jun 12 |
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|
| Jun 5 |
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 29 |
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
|
| May 23 |
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
|
| May 22 |
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
|
